Storage and handling
Store below 77F (25C) Avoid direct sunlight
Store below 77F (25C) Avoid direct sunlight
ACTIVE INGREDIENTS:
Lidocaine 0.5% External Analgesic
Menthol 5% External Analgesic/Counterirritant
Capsaicin 0.0375% External Analgesic
Methyl Salicylate 2% External Analgesic
USES:
Use for temporary relief of minor aches and muscle pains associated with arthritis, simple
backache, strains, sprains, muscle soreness and stiffness
WARNINGS:
DIRECTIONS:
INACTIVE INGREDIENTS:
Water, Glycerine, Sodium Polyacrylate, Polysorbate 80, Aloe
Barbadensis Leaf (Aloe Vera Gel) Juice, EDTA Disodium salt,
Diazolidinyl Urea, Methylparaben, Iodopropynyl Butylcabamate,
Propylparaben
Store below 77F (25C)
Avoid direct sunlight
Soothee Patch
Better-Rx Manufacturing
The potential exists for a small child or pet to suffer serious
effect from chewing or ingesting a new or used Soothee Patch,
although the risk with this formulation has not been evaluated.
It is important for pateints to store and dispose of Soothee
Patch out of the reach of children, pets and others. (See
HANDLING AND DISPOSAL)
Excessive Dosing
Excessive Dosing by applying Soothee Patch to larger areas for
longer than recommmended wearing time could result in increased absorption and higher blood concentrations. Longer
duration of application, application of more than the
recommended number of patches, smaller patients,
or impaired elimination may all contribute to increasing the blood concentration.
PRECAUTIONS
General
Allergic Reactions
Patients allergic to menthol or capsaicin or any other
ingredient in Soothee Patch should not use the Soothee Patch.
Non-intact Skin
Application tobroken or inflamed skin, although not tested,
may result in higher blood concentrations from increased absorption.
Eye Exposure
The contact of Soothee Patch with eyes, altough not studied, should be avoided
based on the findings of sever eye irritations with the use of similar products in animals.
If eye contact occurs, immediately wash out the eye with water or saline.
Pregnancy
Nursing Mothers
Soothee Patch has not been studied in nursing mothers.
Caution should be exercised when administering the Soothee
Patch to nursing mothers. When soothee patch is used concurrently with other products in the same class
Pediatric Use
Soothee Patch Safety and effectiveness has not been established in pediatric patients.
DOSAGE AND ADMINISTRATION
Apply Soothee Patch to intact skin to cover the area most
sensitive to pain. Apply up to four (4) patches per day. Each
patch should not be applied for more than 8 hours in a given
24-hour period. Patches may be cut into smaller sizes with scissors
prior to removal of the release liner. Clothing may be worn over the area of application.
Smaller areas of treatment are recommended in a debilitated patient, or patient with impaired elimination.
If irritation or a burning sensation occurs during application,
remove the patch and do not reapply until the irritation subsides. When Soothee Patch is used
concomitantly with other products containing same or similar agents, the amount
absorbed from all formulations must be considered.
HANDLING AND DISPOSAL
Hands should be washed after handling Soothee Patch, and eye contact
with Soothee Patch should be avoided. Do not store patch outside the sealed envelope.
Apply immediately after removal from the protective envelope. Fold use patches so that the adhesive
side sticks to itself and safely discard used patches or pieces of cut patches where children and pets
cannot get to them. Soothee Patch should be kept out of reach of children.
HOW SUPPLIED
Soothee Patch (Lidocaine 0.5%/Menthol 5%/Capsaicin
0.0375%/Methyl Salicylate 2%) is available as the following:
Box of 15 patches, packaged into 3 child-resistant envelopes (5
patches /envelope)
Patient Information
Soothee Patch is dispensed by prescription (Rx) under medical supervision and direction
Product Code: 69592-001-01
Better-Rx Manufacturing does not represent this product code to be a National Drug Codes
(NDC). Product Codes are formatted according to standard industry practice, to meet the
formatting requirements of pharmacy and health insurance computer systems.
Store below 77F (25C); excursion permitted to 59-85F (15-30C) See USP Controlled Room Temperature.
Manufactured for:
Better-Rx Manufacturing
122 E Rose Lane No.C Houston Tx 77076
For questions or comments please call 1-800-311-6046
March 2015
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1728301 | capsaicin 0.0375 % / lidocaine 0.5 % / menthol 5 % / methyl salicylate 2 % Medicated Patch | PSN | 1 |
| 1728301 | capsaicin 0.000375 MG/MG / lidocaine 0.005 MG/MG / menthol 0.05 MG/MG / methyl salicylate 0.02 MG/MG Medicated Patch | SCD | 1 |
| 1728301 | capsaicin 0.0375 % / lidocaine 0.5 % / menthol 5 % / methyl salicylate 2 % Medicated Patch | SY | 1 |
| Class | Version | Type | Effective |
|---|---|---|---|
| LIDOCAINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 473d070d-1c38-488e-b991-c4d1bf45aab8 | Product name | 1 | 20210201 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 69592-001-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-0a05-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 69592-001-01 | Soothee Patch | 15 in 1 BOX | PATCH | 15 | 1 | |
| 69592-001-01 | Soothee Patch | 10 g in 1 PATCH | PATCH | 10 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CAPSAICIN | ACTIVE INGREDIENT | S07O44R1ZM | 1 | |
| LIDOCAINE | ACTIVE INGREDIENT | 98PI200987 | 1 | |
| MENTHOL | ACTIVE INGREDIENT | L7T10EIP3A | 1 | |
| METHYL SALICYLATE | ACTIVE INGREDIENT | LAV5U5022Y | 1 | |
| CAPSAICIN | ACTIVE MOIETY | S07O44R1ZM | 1 | |
| LIDOCAINE | ACTIVE MOIETY | 98PI200987 | 1 | |
| MENTHOL | ACTIVE MOIETY | L7T10EIP3A | 1 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 1 | |
| ALOE VERA LEAF | INACTIVE INGREDIENT | ZY81Z83H0X | 1 | |
| DIAZOLIDINYL UREA | INACTIVE INGREDIENT | H5RIZ3MPW4 | 1 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| IODOPROPYNYL BUTYLCARBAMATE | INACTIVE INGREDIENT | 603P14DHEB | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| POLYSORBATE 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| SODIUM POLYACRYLATE (2500000 MW) | INACTIVE INGREDIENT | 05I15JNI2J | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 69592-001 | 69592-001-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LIDOCAINE | 98PI200987 | ACTIB |
| MENTHOL | L7T10EIP3A | ACTIB |
| CAPSAICIN | S07O44R1ZM | ACTIB |
| METHYL SALICYLATE | LAV5U5022Y | ACTIB |
| WATER | 059QF0KO0R | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| SODIUM POLYACRYLATE (2500000 MW) | 05I15JNI2J | IACT |
| POLYSORBATE 80 | 6OZP39ZG8H | IACT |
| ALOE VERA LEAF | ZY81Z83H0X | IACT |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| DIAZOLIDINYL UREA | H5RIZ3MPW4 | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| IODOPROPYNYL BUTYLCARBAMATE | 603P14DHEB | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 0.4 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / TOPICAL | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION/ DROPS / AURICULAR (OTIC) | 13 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE, DELAYED RELEASE / ORAL | 23 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE, LIQUID FILLED / ORAL | 24 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER, FOR SUSPENSION / ORAL | 8 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / OPHTHALMIC | 4 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / NASAL | 140 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | GEL / VAGINAL | 5 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / EPIDURAL | 30 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION / INTRAVENOUS | 4680 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, EXTENDED RELEASE / ORAL | 0.12 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CONCENTRATE / ORAL | 12 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET / ORAL | 100 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / INTRAMUSCULAR | 0.02 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SYSTEM / TOPICAL | 126 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | CAPSULE / ORAL | 418.37 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PERINEURAL | 80 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRAVENOUS | 6 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / ORAL | 1 mg/1ml | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SYSTEM / IONTOPHORESIS | 0.1 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / ORAL | 100 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / SOFT TISSUE | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / PARENTERAL | 30 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | GEL / OPHTHALMIC | 396 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, CHEWABLE / ORAL | 1.28 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRAVITREAL | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ELIXIR / ORAL | 800 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | PASTE, DENTIFRICE / DENTAL | 0.05 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / SUBCUTANEOUS | 0.02 %w/v | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / RESPIRATORY (INHALATION) | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | GEL / TRANSDERMAL | 1 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | EMULSION / OPHTHALMIC | 26 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUPPOSITORY / RECTAL | 72.15 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | DROPS / AURICULAR (OTIC) | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET / ORAL | 1.8 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRACARDIAC | 2 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | AEROSOL, FOAM / VAGINAL | 3 %w/w | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | LIQUID / INTRAVENOUS | 720 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / OPHTHALMIC | 0.06 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRAVENOUS | 10 %w/v | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / AURICULAR (OTIC) | 1 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 4fef7bc1-f035-46bd-b46f-b4d305f614e7 | aed1e7c1-6197-4152-ae5e-06cf2ec3020f | 2015-03-19 | Warnings | 4fef7bc1-f035-46bd-b46f-b4d305f614e7 aed1e7c1-6197-4152-ae5e-06cf2ec3020f |
Adverse event summaries are temporarily unavailable. Other product information remains available.